REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
9

10 Weeks on CJC-1295 (no DAC) — Full Update

Jules Griffin·about 2 months ago
Ten weeks on CJC-1295 (no DAC) — here is the full update. Started this partly out of curiosity and partly because I was dealing with nagging recovery issues that were limiting my training. Week 1-2: nothing notable. Getting used to the injection routine. Week 3-4: first signs of improved sleep. Starting to feel more rested upon waking. Week 5-6: recovery improvements become clear. A particularly brutal leg day had me back to normal in about 36 hours instead of the usual 72. Week 7-8: feeling good. Benefits have stabilized. Training volume is up about 15 percent compared to pre-protocol. Week 9-10: still going strong. Bloodwork at week 8 came back looking good with no concerning changes. The biggest surprise was how much the sleep improvement affected everything else. Better sleep led to better recovery, which led to better training, which led to better results. It was a positive cascade effect. One caveat: I also cleaned up my diet and improved my sleep hygiene around week 2, so I cannot attribute 100 percent of the improvements to CJC-1295 (no DAC) alone.

Comments (4)

Avery KirklandDEMO·about 2 months ago

Interesting data. My CJC-1295 (no DAC) experience was somewhat different — I noticed effects earlier than you did, probably because I started at a higher initial dose. Trade-off was more pronounced side effects in week 1 that resolved by week 2. Neither approach is wrong, just different risk-reward profiles.

4
Sawyer CarpenterDEMO·about 2 months ago

This thread has been incredibly helpful for understanding CJC-1295 (no DAC). I have been on the fence about starting for months and reading detailed real-world experiences like these has been more useful than any blog post or article I have found. The fact that most reports here are moderate rather than extreme actually increases my confidence.

5
Taylor HenryDEMO·about 2 months ago

One thing I wish more CJC-1295 (no DAC) discussions covered is the discontinuation experience. What happens when you stop? In my case, the benefits gradually faded over about 3-4 weeks after stopping. Sleep was the first thing to return to baseline. Recovery improvements lasted a bit longer. Worth knowing for planning protocol duration.

2
Ever FinchDEMO·about 2 months ago

Great point about bloodwork. I ran comprehensive panels at baseline, 6 weeks, and 12 weeks during my CJC-1295 (no DAC) protocol. The most informative markers for me were inflammatory markers and IGF-1 levels. Would strongly recommend anyone running CJC-1295 (no DAC) to invest in proper monitoring.

3

Sign in to comment.